Prospects for Local Application of Antiresorptive Drugs in Skeleton Bone Injuries and Diseases



Cite item

Full Text

Abstract

Increase in bone tissue resorption intensity on the border “metal - bone” as a compulsory component of remodeling in systemic osteoporosis or other metabolic osteopathies may result in poor surgical treatment results. Present review is dedicated to the analysis of available data on the possibility of local bisphosphonates application for the depression of resorption process in the zone of surgical intervention. In some works it is noted that just the local use of bisphosphonates is more effective for the normalization of remodeling and provision of biologic stability of the implants.

About the authors

S. S Rodionova

Central Institute of Traumatology and Orthopaedics named after N.N. Priorov, Moscow

Email: rod06@inbox.ru

M. V Lekishvili

Central Institute of Traumatology and Orthopaedics named after N.N. Priorov, Moscow

E. D Sklyanchuk

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow

A. N Torgashin

Central Institute of Traumatology and Orthopaedics named after N.N. Priorov, Moscow

A. Yu Ryabov

Stomatologic Center “Interdentos”, Korolyov

Yu. B Yurasova

Russian Children's Clinical Hospital, Moscow, Russia

References

  1. Shanbhag A.S. Use of bisphosphonates to improve the durability of total joint replacements. J. Am Academy Orthop. Surg. 2006; 14 (4): 215-25.
  2. Astrand J., Aspenberg P. Alendronate did not inhibit instability-induced bone resorption. A study in rats. Acta Orthop. Scand. 1999; 70 (1): 67-70.
  3. Bauer T.W., Smith S.T. Bioactive materials in orthopaedic surgery: overview and regulatory considerations. Clin. Orthop. Relat. Res. 2002; 395: 11-22.
  4. Kanis J.A., Adams J., Borgström F., Cooper C., Jönsson B., Preedy D. et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone. 2008; 42 (1): 4-15.
  5. Svedbom A., Hernlund E., Ivergård M., Compston J., Cooper C., Stenmark J. et al. Osteoporosis in the European Union: a compendium of country-specific reports Osteoporosis in the European Union: a compendium of country-specific reports. Arch. Osteoporos. 2013; 8 (1-2): 137.
  6. Plotkin L.I., Lezcano V., Thostenson J., Weinstein R.S., Manolagas S.C., Bellido T. Connexin Is Required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J. Bone Miner Res. 2008; 23 (11): 1712-21.
  7. Chapurlat R.D., Arlot M., Burt-Pichat B. Chavassieux P., Roux J.P., Portero-Muzy N. et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J. Bone Miner. Res. 2008; 23 (7): 1150-1.
  8. Cranney А., Wells G., Willan A. et al. The osteoporosis methodology group and the osteoporosis research advisory group. Meta-analysis of alendronate for the treatment of postmenopausal women: ten years experience with alendronate for osteoporosis in postmenopausal women. Endocrine Reviews. 2002; 23 (4): 508-16.
  9. Matuszewski Ł., Turżańska K., Matuszewska A. Jabłoński M., Polkowska I., Mazurkiewicz T. Effect of implanted bisphosphonate-enriched cement on the trabecular microarchitecture of bone in a rat model using micro-computed tomography. Int Orthop. (SICOT). 2013; 37: 1187-93.
  10. Faucheux C., Verron E., Soueidan A., Josse S., Arshad M.D., Janvier P. et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J. Biomed. Mater. Res. A. 2009; 89 (1): 46-56.
  11. Russell R.G.G., Watts N.B., Ebetino F.H., Rogers M.J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis Int. 2008; 19 (6): 733-59.
  12. Fleisch H. Mechanisms of action of the bisphosphonates. Medicina (B Aires). 1997; 57 (Suppl 1): 65-75.
  13. Greiner S.H., Kadow-Romacker A., Lubberstedt M. Schmidmaier G., Wildemann B. The effect of zoledronic acid incorporated in a poly(D,L-lactide) implant coating on osteoblasts in vitro J. Biomed Mater. Res. A. 2006; 80 (4): 769-75.
  14. Millett P.J., Allen M.J., Bostrom M.P. Effects of alendronate on particle-induced osteolysis in a rat model. J. Bone Joint Surg. Am. 2002; 84 (2): 236-49.
  15. Stadelmann V.A., Terrier A., Gauthier O. Bouler J.M., Pioletti D.P. Prediction of bone density around orthopedic implants delivering bisphosphonate. J. Biomechanics. 2009; 42 (9): 1206-11.
  16. Bone H.G., Hosking D., Devogelaer J., Tucci J.R., Emkey R.D., Tonino R.P. et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 2004; 350: 1189-99.
  17. Hu J.U., Ding M., Soballe K., Bechtokd J.E., Danielsen C.C., Day J.S. et al. Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone. Bone. 2002; 31 (5): 591-7.
  18. Arabmotlagh M., Rittmeister M., Hcnnigs T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J. Orthop. Res. 2006; 24 (7): 1336-41.
  19. Родионова С.С., Тургумбаев Т.Н. Применение алендроната в послеоперационном периоде для профилактики асептической нестабильности эндопротеза тазобедренного сустава. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2009; 3: 36-44.
  20. Bhandari M., Bajammal S., Guyatt G.H. Griffith L, Busse JW, Schünemann H,et al. Effect of bisphosphonates on periprosthetic bone mineral density after total joint arthroplasty. A meta-analysis. J. Bone Joint Surg. Am. 2005; 87 (2): 293-301.
  21. Chacon G.E., Stine E.A., Larsen P.E. Beck F.M., McGlumphy E.A. Effect of alendronate on endosseous implant integration: an in vivo study in rabbits. J. Oral Maxillofac. Surg. 2006; 64 (7): 1005-9.
  22. Astrand J., Aspenberg P. Reduction of instability-induced bone resorption using bisphosphonates: high doses are needed in rats. Acta Orthop. Scand. 2002; 73: 24-30.
  23. Aspenberg P., Herbertsson P. Periprosthelic bone resorption. Particles versus movement. J. Bone Joint Surg. Br. 1996; 78 (4): 641-6.
  24. Gut G., Sladowski D. Mechanical properties of bone fixation devices prepared from a human allogenic bone. Transplant Proc. 2007; 39 (9): 2920-2.
  25. Faucheux C., Verron E., Soueidan A., Josse S., Arshad M.D., Janvier P. et al. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J. Biomed. Mater. Res. 2009; 1: 46-56.
  26. Greiner S.H., Kadow-Romacker A., Wildemann B. Schwabe P., Schmidmaier G. Bisphosphonates incorporated in a poly(D,L-lactide) implant coating inhibit osteoblast like cells in vitro. J. Biomed Mater. Res. 2007; 83 (4): 1184-91.
  27. Aspenberg P., Astrand J. Bone allografts pretreated with a bisphosphonate are not resorbed. Acta Orthop. Scand. 2002; 73 (1): 20-3.
  28. Astrand J., Aspenberg P. Topical, single dose bisphosphonate treatment reduced bone resorption in a rat model for prosthetic loosening. J. Orthop. Res. 2004; 22 (2): 244-9.
  29. Gao Y., Zou S., Liu X., Bao C., Hu J. The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials. 2009; 30 (9): 1790-6.
  30. Greiner S.H., Wildemann B., Back D.A., Alidoust M., Schwabe P., Haas N.P. et al. Local application of zoledronic acid incorporated in a poly (D,L-lactide) coated implant accelerates fracture healing in rats. Acta Orthop. 2008; 79 (5): 717-25.
  31. Bobyn J.D., Hacking S.A., Krygier J.J., Harvey E.J., Little D.G., Tanzer M. Zoledronic acid causes enhancement of bone growth into porous implants. J. Bone Joint Surg. Br. 2005; 87 (3): 416-20.
  32. Ding M., Day J.S., Burr D.B. Mashiba T., Hirano T., Weinans H. et al. Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcified Tissue Int. 2003; 72 (6): 737-44.
  33. Jakobsen T., Kold S., Bechtold J.E., Elmengaard B., Søballe K. Effect of topical alendronate treatment on fixation of implants inserted with bone compaction. Clin Orthop. Relat. Res. 2006; 444: 229-34.
  34. Jakobsen T., Baas J., Bechtold J.E., Elmengaard B., Søballe K. Soaking morselized allograft in bisphosphonate can impair implant fixation. Clin. Orthop. Relat. Res. 2007; 463: 195-201.
  35. Jakobsen T., Kold S., Bechtold J.E., Elmengaard B., Søballe K. Local alendronate increases fixation of implants inserted with bone compaction: 12-week canine study. J. Orthop. Res. 2007; 25 (4): 432-41.
  36. Jakobsen T., Baas J., Bechtold J.E., Elmengaard B., Søballe K. The effect of soaking allograft in bisphosphonate. Clin Orthop. Relat. Res. 2010; 468: 867-74.
  37. Jakobsen T., Baas J., Bechtold J.E., Elmengaard B., Søballe K. The effect on implant fixation of soaking tricalcium phosphate granules in bisphosphonate. Open Orthop. J. 2012; 6: 371-5.
  38. Søballe K., Chen X., Jensen T.B. Kidder L., Bechtold J.E. Alendronate treatment in the revision setting, with and without controlled implant motion: an experimental study in dogs. Acta Orthop. 2007; 78 (6): 800-7.
  39. Tanzer M., Karabasz D., Krygier J.J. Cohen R., Bobyn J.D. Bone augmentation around and within porous implants by local bisphosphonate elution. Clin. Orthop. Relat. Res. 2005; 441: 30-9.
  40. DiResta G.R., Manoso M,W., Naqvi A., Zanzonico P., Smith-Jones P., Tyler W. et al. Bisphosphonate delivery to tubular bone allografts. Clin Orthop. Relat. Res. 2008; 466: 1871-9.
  41. Xue Q., Li H., Zou X., Bünger M., Egund N., Lind M. et al. Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion. Eur. Spine J. 2005; 14 (3): 222-6.
  42. Jakobsen T., Baas J., Kold S., Bechtold J.E., Elmengaard B., Søballe K. Local bisphosphonate treatment increases fixation of hydroxyapatite-coated implants inserted with bone compaction. J. Orthop. Res. 2009; 27 (2): 189-94.
  43. Abtahi J., Agholme F., Sandberg O., Aspenberg P. Effect of local vs. systemic bisphosphonate delivery on dental implant fixation in a model of osteonecrosis of the jaw. J. Dental Research. 2013; 92 (3): 279-83.
  44. Millett P.J., Allen M.J., Bostrom M.P. Effects of alendronate on particle-induced osteolysis in a rat model. J. Bone Joint Surg. Am. 2002; 84 (2): 236-49.
  45. Åberg J., Brohede U., Mihranyan A. et al. Targeted local delivery of bisphosphonate from orthopaedic implants. Key Engineering Materials. 2008; Bioceramics 21: 543-46.
  46. Åberg J., Brohede U., Mihranyan A., Strømme M., Engqvist H. Bisphosphonate incorporation in surgical implant coatings by fast loading and co-precipitation at low drug concentrations. J. Mater Sci Mater. Med. 2009; 20 (10): 2053-61.
  47. Meraw S.J., Reeve C.M., Wollan P.C. Use of alendronate in peri-implant defect regeneration. J. Periodontol. 1999; 70 (2): 151-8.
  48. Ozturk A.M., Tabak A.Y., Aktekin C.N., Altay M., Erdemli E., Karahuseyinoglu S. et al. Alendronate enhances antibiotic-impregnated bone grafts in the treatment of osteomyelitis. Int. Orthop. 2008; 32 (6): 821-7.
  49. McKenzie K., Dennis Bobyn J., Roberts J., Karabasz D., Tanzer M. Bisphosphonate remains highly localized after elution from porous implants. Clin. Orthop. Relat. Res. 2011; 469 (2): 514-22.
  50. Родионова С.С., Еловой-Вронский А.А. Связь эффективности комбинированного использования ибандроновой кислоты и альфакальцидола с ремоделированием костной ткани у женщин с постменопаузальной формой остеопороза. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2011; 4: 45-9.
  51. Back D.A., Pauly S., Romme L. Haas N.P., Schmidmaier G., Wildemann B. et al. Effect of local zoledronate on implant osseointegration in a rat model. BMC Musculoskelet. Disord. 2012; 13: 42.
  52. Gao Y., Zou S., Liu X., Bao C., Hu J. The effect of surface immobilized bisphosphonates on the fixation of hydroxyapatite-coated titanium implants in ovariectomized rats. Biomaterials. 2009; 30 (9): 1790-6.
  53. Agholme F., Aspenberg P. Experimental results of combining bisphosphonates with allograft in a rat model. J. Bone Joint Surg. Br. 2009; 91 (5): 670-5.
  54. Gangoiti M.V., Cortizo A.M., Arnol V. Felice J.I., McCarthy A.D. Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J. Pharmacol. 2008; 600 (1-3): 140-7.
  55. Stadelmann V.A., Terrier A., Gauthier O., Bouler J.M., Pioletti D.P. Prediction of bone density around orthopedic implants delivering bisphosphonate. J. Biomechanics. 2009; 42 (9): 1206-11.
  56. Родионова С.С., Торгашин А.Н., Лекишвили М.В., Семенова Л.А., Морозов А.К. Влияние бисфосфонатов в составе биокомпозиционного материала на костеобразование и минерализацию кости. Вестник травматологии и ортопедии им. Н.Н. Приорова. 2011; 2: 59-66.
  57. Matos М.А., Tannuri U., Guarniero R. The effect of zoledronate during bone healing. J. Orthopaed Traumatol. 2010; 11: 7-12.
  58. Nancollas G.H., Tang R., Phipps R.J. Henneman Z., Gulde S., Wu W. et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006; 38 (5): 617-27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-76249 от 19.07.2019.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies